Teva Announces Launch of Generic Epiduo® in the United States

Teva Pharmaceutical Industries Ltd. announced the launch of generic Epiduo®1 (adapalene and benzoyl peroxide) gel, 0.1%/2.5% in the U.S.

Adapalene and benzoyl peroxide gel 0.1%/2.5% is a combination of adapalene, a retinoid, and benzoyl peroxide, and is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

“I am very pleased that Teva is introducing another first generic product, bringing value to our patients and savings to the US healthcare system,” said Andy Boyer, President & CEO, Global Generic Medicines, North America.”

Teva was the first company to file a generic application for Epiduo and is expected to benefit from 180-days of generic product exclusivity. This launch marks the most recent addition to Teva’s portfolio of over 40 dermatology products.

“This is an extremely important development for Teva in our desire to make a meaningful difference to the millions of patients who suffer from acne in the U.S.,” said Hafrun Fridriksdottir, Ph.D., EVP, President of Global Generics R&D.

With close to 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva product.

Adapalene and benzoyl peroxide gel 0.1%/2.5% had annual sales of approximately $251 million in the U.S. according to IMS data as of March 2017.

About Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% Adapalene and benzoyl peroxide gel 0.1%/2.5% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

About Teva
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva’s net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

Teva Pharmaceutical Industries Ltd.
IR Contacts:
United States
Kevin C. Mannix, 215-591-8912

or

Ran Meir, 215-591-3033

or

Israel
Tomer Amitai, 972 (3) 926-7656

or

PR Contacts:
Israel
Iris Beck Codner, 972 (3) 926-7208

or

United States
Denise Bradley, 215-591-8974

source:worldpharmatoday

Seo wordpress plugin by www.seowizard.org.